Clinical and Molecular Treatment of Gastrointestinal and Helicobacter pylori Disorders

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 4613

Special Issue Editor

E-Mail Website
Guest Editor
The Hormel Institute, University of Minnesota, Austin, MN 55912, USA
Interests: inflammation and cancer biology; immunology and bacterial pathogenesis; mitochondrial metabolism; post-translational modification; dietary agents; drug discovery; protein structure biology; life-style and environmental cancer; risk factors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Helicobacter pylori (H. pylori) is a major causative agent of chronic gastritis, gastric ulcers, and gastric carcinoma. H.-pylori-cytotoxin-associated antigen A (CagA) plays a crucial role in the development of gastric cancer. It is a gram negative, spiral-shaped, microaerophilic, and flagellated microorganism. More than 50% of the world population is colonized by H. pylori; however, only some people suffer from active disease depending on different factors such as age, gender, crowding, hyperacidity, smoking habit, and poor socioeconomic status. Developing countries have a high H. pylori prevalence rate of 80% compared with the rate in developed countries (20–50%). An epidemiological study in 1991 reported a link between H. pylori and gastric cancer and, in 1994, the World Health Organization (WHO) International Agency for Research on Cancer (IARC) classified H. pylori as a class I carcinogen (carcinogenic to humans).

Gastrointestinal cancers are among the highest death causing cancers in the world. The incidence of these cancers was an estimated 4.8 million cases and 3.4 million deaths worldwide. Gastrointestinal cancer is a group of cancers that affect the gastrointestinal tract. Gastrointestinal cancer includes esophageal, stomach, gallbladder, gastrointestinal stromal tumor, liver, pancreatic, colon, rectal, and anal cancers. Through this Special Issue, “Clinical and Molecular Treatment of Gastrointestinal and Helicobacter pylori Disorder”, we aim to highlight the new discoveries and advances in the mechanism, diagnosis, prevention, and treatment of gastrointestinal and Helicobacter pylori disorders.

We encourage contributions that are focused on, but are not limited to, the following themes:

  • Lifestyle factors;
  • Natural occurring exposures;
  • Medical treatments;
  • New drug treatment approaches for infection or inflammation or cancer;
  • Dietary-associated treatment;
  • Formation of advanced or combination treatment approaches for infection, inflammation, and cancers;
  • Host‒pathogen interactions.

We are looking forward to your contributions.

Dr. Faisal Aziz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • gastrointestinal
  • Helicobacter pylori
  • dietary patterns
  • infectious disease
  • cancer
  • precision medicine
  • immune and targeted therapeutics
  • radiotherapy
  • cytotoxicity
  • drugs
  • clinical applications

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


34 pages, 3729 KiB  
A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management
by Qamar Sultana, Jill Kar, Amogh Verma, Shreya Sanghvi, Nirja Kaka, Neil Patel, Yashendra Sethi, Hitesh Chopra, Mohammad Amjad Kamal and Nigel H. Greig
J. Clin. Med. 2023, 12(15), 5138; - 05 Aug 2023
Cited by 2 | Viewed by 4411
Neuroendocrine neoplasms (NENs) are a group of heterogeneous tumors with neuroendocrine differentiation that can arise from any organ. They account for 2% of all malignancies in the United States. A significant proportion of NEN patients experience endocrine imbalances consequent to increased amine or [...] Read more.
Neuroendocrine neoplasms (NENs) are a group of heterogeneous tumors with neuroendocrine differentiation that can arise from any organ. They account for 2% of all malignancies in the United States. A significant proportion of NEN patients experience endocrine imbalances consequent to increased amine or peptide hormone secretion, impacting their quality of life and prognosis. Over the last decade, pathologic categorization, diagnostic techniques and therapeutic choices for NENs—both well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs)—have appreciably evolved. Diagnosis of NEN mostly follows a suspicion from clinical features or incidental imaging findings. Hormonal or non-hormonal biomarkers (like serum serotonin, urine 5-HIAA, gastrin and VIP) and histology of a suspected NEN is, therefore, critical for both confirmation of the diagnosis and classification as an NET or NEC. Therapy for NENs has progressed recently based on a better molecular understanding, including the involvement of mTOR, VEGF and peptide receptor radionuclide therapy (PRRT), which add to the growing evidence supporting the possibility of treatment beyond complete resection. As the incidence of NENs is on the rise in the United States and several other countries, physicians are more likely to see these cases, and their better understanding may support earlier diagnosis and tailoring treatment to the patient. We have compiled clinically significant evidence for NENs, including relevant changes to clinical practice that have greatly updated our diagnostic and therapeutic approach for NEN patients. Full article
Show Figures

Graphical abstract

Back to TopTop